Dr Geoff Oxnard outlines promising results from the key studies from 2020 on the neoadjuvant or adjuvant treatment of resectable and/or nonmetastatic NSCLC, as well as the value of stereotactic body radiotherapy in place of surgery during the COVID-19 pandemic.
Related Items
TOP - September 2022 Vol 15, No 5 published on September 15, 2022 in Lung Cancer
TOP - September 2021 Vol 14, No 5 published on September 7, 2021 in Lung Cancer
TOP - May 2021 Vol 14, No 3 published on May 14, 2021 in Lung Cancer
Last modified: July 22, 2021